Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Conversion to Segment 4-1 ALPPS Associated With Right Bile Duct Section and Exte...
Journal Information
Vol. 95. Issue 6.
Pages 354-357 (June - July 2017)
Vol. 95. Issue 6.
Pages 354-357 (June - July 2017)
Scientific letter
Full text access
Conversion to Segment 4-1 ALPPS Associated With Right Bile Duct Section and External Tube for the Control of Progression Through the Bile Duct of Colorectal Metastases
Conversión a ALPPS segmento 4-1 con sección de vía biliar derecha y drenaje externo como técnica de control de progresión tumoral biliar de metástasis colorrectal
Visits
2275
Oscar Alonso Casadoa,
Corresponding author
oalonso@mdanderson.es

Corresponding author.
, Gloria Ortega Péreza, Sara Encinas Garcíab, Raquel Saiz Martínezc, Santiago González Morenoa
a Unidad de Oncología Quirúrgica Digestiva, MD Anderson Cancer Center Madrid, Madrid, Spain
b Unidad de Oncología Médica Digestiva, MD Anderson Cancer Center Madrid, Madrid, Spain
c Unidad de Radiodiagnóstico, MD Anderson Cancer Center Madrid, Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Full Text

Surgical resection continues to be the best treatment option for colorectal cancer liver metastases. In cases with bilobar metastases, the residual liver volume (RLV) is usually a limiting factor. Portal vein ligation or embolization makes the necessary RLV attainable in 3–4 weeks.1 With the ALPPS technique and its variations, important hypertrophy can be achieved in one week. However, it is not always functional, and the reported morbidity and mortality rates, although variable, are high, while the long-term oncological results are unknown.2–5

We present the case of a 59-year-old patient with no prior history of interest who had been diagnosed 6 years earlier with a moderately differentiated adenocarcinoma in the descending colon (pT3N2M0, mutated k-ras). She was treated with left hemicolectomy and 12 cycles of adjuvant FOLFOX at a referral hospital. Three years later, 2 hepatic metastases were detected in segments 2 and 7, which were treated with left lateral sectionectomy and radiofrequency ablation in segment 7. The patient was administered 12 cycles of perioperative FOLFIRI-bevacizumab. Two years later, hepatic recurrence was detected in segment 7 with extension to the bile duct of this segment as well as the right posterior bile duct. After receiving 3 cycles of FOLFIRINOX-bevacizumab, the patient was referred to our hospital, where we completed the study with magnetic resonance cholangiopancreatography (MRCP) and volumetric imaging. MRI showed a 5cm tumor in segment 7, which infiltrated and progressed along the right posterior bile duct, without reaching the anterior duct (Fig. 1A–C). Volumetric imaging showed a 23% RLV (316cc) for right hepatectomy and 80% (1099cc) for right posterior sectionectomy. We planned a resection using right posterior sectionectomy, with intraoperative biopsy of the biliary margin. If microscopic infiltration were detected, we would proceed with right portal ligation and right hepatectomy in a second phase. We currently prefer a 2-stage surgery with portal ligation or embolization until the ALPPS technique and results become more standardized.

Fig. 1.

(A) Metastasis in segment 7; (B) infiltration of the right posterior bile duct (arrow indicating infiltration limit 21mm from the anterior duct); (C) MRCP with no dilatation or stenosis; (D) volume CT on the 7th day post-op after the first stage

(0.19MB).

After performing right subcostal laparotomy, we found a mass measuring 5cm in segment 7 and absence of segments 2 and 3. Intraoperative ultrasound showed tumor progression through the right posterior bile duct, and the anterior duct was normal. We performed right posterior sectionectomy. After parenchymal division with hilar clamping for 14min, we divided the portal triad of this sector at the confluence with the right anterior sector, finding that there was macroscopic infiltration in this area. Choledocoscopy ruled out infiltration of the biliary confluence and right hepatic duct. In this situation, we decided to conduct a 2-stage right hepatectomy inwith the ALPPS technique of segments 4-1,6 dividing the right bile duct and placing 2 external biliary drains. We performed the parenchymal dissection following the Cantlie line up to the vena cava, with no hilar clamping. We proceeded with ligation and dissection of the right portal vein and identification of the artery with a vessel loop (Fig. 2A). After dividing the right hepatic duct, we placed a drain tube in each visualized duct; these were affixed with a purse-string suture to the bile ducts to achieve watertightness (Fig. 2B). Intraoperative biopsy of the margin of the right bile duct specimen was identified as malignant. We left 2 subhepatic and subphrenic suction drains and TachoSil® patches on the liver surface.

Fig. 2.

(A) 1st stage: partition of the liver along the Cantlie line; vessel loop on the artery; (B) 2nd stage: external biliary drains; (C) liver remnant; (D) resection specimen: black arrow indicating the tumor in the bile duct, white arrow indicating bile resection margin.

(0.29MB).

The postoperative patient progress was satisfactory with functioning biliary drains as soon as the patient left the operating room. We administered somatostatin in perfusion from the ligation of the portal vein until the 7th day post-op. Lab work on day 5 showed: prothrombin 73%; INR 1.2; TB 0.9mg/dL (MELD=8). Volumetric study on the 7th day post-op (Fig. 1D) showed hypertrophy of the remaining liver (segments 1 and 4), with an RLV of 41% (561cc, 0.82% of body weight, 77% increase over the initial RLV).

The second stage was performed on the 12th day post-op (following the clinical criteria established by the international registry3 to minimize the risk of postoperative mortality): re-laparotomy, identification and dissection of the right hepatic artery, retrohepatic veins and right suprahepatic vein. Somatostatin was perfused from the ligation of the artery until the 7th day post-op. In the postoperative period, the patient had mild hepatic dysfunction (5th day post-op: prothrombin 54%; INR 1.5; TB: 2.1. mg/dL) that was improving upon discharge on the 15th day post-op (prothrombin 63%; INR 1.3, BT 1.6). The pathological study showed no tumor in the margins of the bile duct section (Fig. 2D).

Progression of colorectal metastasis through the biliary tract has already been described by other authors.7,8 Infiltration of the main biliary tract worsens prognosis and, in this case, could impede R0 resection. The presence of a macroscopic tumor made us fear that in 3–4 weeks the common hepatic duct would be infiltrated. We needed to achieve hypertrophy of segments 1 and 4 as soon as possible, while at the same time slowing the progression of the tumor through the bile duct. Recently, a series of cases of monosegment ALPPS hepatectomy (including 3 cases of segment 1-4 ALPPS) has been published with good results.9 We added the technical variation of dissection and external drainage of the bile duct, which prevented tumor progression during the interval until the second procedure, a method which has not been previously described. Regardless of the criticism or controversy that the ALPPS technique may raise, there is no doubt that in some cases it can be a useful resource.

References
[1]
J. Shindoh, J.N. Vauthey, G. Zimmitti, S.A. Curley, S.Y. Huang, A. Mahvash, et al.
Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach.
J Am Coll Surg, 217 (2013), pp. 126-133
[2]
S. Truant, O. Scatton, S. Dokmak, J.M. Regimbeau, V. Lucidi, A. Laurent, et al.
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): impact of the inter-stages course on morbi-mortality and implications for management.
E J Surg Oncol, 41 (2015), pp. 674-682
[3]
E. Schadde, D.A. Raptis, A.A. Schnitzbauer, V. Ardiles, C. Tschuor, M. Lesurtel, et al.
Prediction of mortality after ALPPS stage-1. An analysis of 320 patients from the International ALPPS Registry.
Ann Surg, 262 (2015), pp. 780-786
[4]
S. Buac, E. Schadde, A.A. Schnitzbauer, K. Vogt, R. Hernandez-Alejandro.
The many faces of ALPPS: surgical indications and techniques among surgeons collaborating in the international registry.
HPB (Oxford), 18 (2016), pp. 442-448
[5]
L. Vigano, M.M. Cimino, G. Torzilli, R. Adam.
Improving the Safety of ALPPS Procedure: The Optimal Compromise Between Dropout and Mortality Risk. Comment on Schadde E et al. Prediction of Mortality After ALPPS Stage-1: an Analysis of 320 Patients From the International ALPPS Registry.
Ann Surg, 262 (2015), pp. 780-786
[6]
M. Linecker, P. Kron, H. Lang, E. Santibañes, P.A. Clavien.
Too many languages in the ALPPS. Preventing another tower of Babel.
Ann Surg, 263 (2016), pp. 837-838
[7]
L.M. Postlewait, M.H. Squires, D.A. Kooby, S.M. Weber, C.R. Scoggins, K. Cardona, et al.
A multi-institutional analysis of 429 patients undergoing major hepatectomy for colorectal cancer liver metastases: the impact of concomitant bile duct resection on survival.
J Surg Oncol, 112 (2015), pp. 524-528
[8]
S. López, E. Ramos, J. Torras, L. Llado, A. Rafecas.
Intrabiliary growth of colorectal liver metastases.
[9]
E. Schadde, M. Malagó, R. Hernández-Alejandro, J. Li, E. Abdalla, V. Ardiles, et al.
Monosegment ALPPS hepatectomy: extending resectability by rapid hypertrophy.
Surgery, 157 (2015), pp. 676-689

Please cite this article as: Alonso Casado O, Ortega Pérez G, Encinas García S, Saiz Martínez R, González Moreno S. Conversión a ALPPS segmento 4-1 con sección de vía biliar derecha y drenaje externo como técnica de control de progresión tumoral biliar de metástasis colorrectal. Cir Esp. 2017;95:354–357.

Copyright © 2016. AEC
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.cireng.2023.03.012
No mostrar más